PAR-1 inhibitors: A novel class of antiplatelet agents for the treatment of patients with atherothrombosis

Handbook of Experimental Pharmacology

Volumn 210, Issue , 2012, Pages 239-260

  Leonardi, Sergio ^a,b   Becker, Richard C ^a,c  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute coronary syndromes; Antiplatelet agents; Atherothrombosis; PAR 1 inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ATOPAXAR; CANGRELOR; CLOPIDOGREL; HEPARIN; PLACEBO; PRASUGREL; PROTEINASE ACTIVATED RECEPTOR 1; PURINERGIC P2Y12 RECEPTOR; SCH 602539; TICAGRELOR; TICLOPIDINE; UNCLASSIFIED DRUG; VORAPAXAR; IMINE; LACTONE; PYRIDINE DERIVATIVE;

ACUTE CORONARY SYNDROME; ARTICLE; BINDING AFFINITY; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DOSE RESPONSE; DOWN REGULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FOLLOW UP; HEART INFARCTION; HUMAN; ISCHEMIA; LIVER FUNCTION; LOADING DRUG DOSE; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NONHUMAN; PRIORITY JOURNAL; QT PROLONGATION; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; ANIMAL; ATHEROSCLEROTIC PLAQUE; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; REVIEW;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; IMINES; LACTONES; PLAQUE, ATHEROSCLEROTIC; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RECEPTOR, PAR-1; THROMBOSIS;

EID: 84867163935     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-29423-5_10     Document Type: Article

References (36)

1. Becker RC, Moliterno DJ, Jennings LK et al (2009) Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, doubleblind, placebo-controlled phase II study. Lancet 373:919-928
2. Bhatt DL, Lincoff AM, Gibson CM et al (2009) Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 361:2330-2341
3. Chackalamannil S, Wang Y, Greenlee WJ et al (2008) Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem 51:3061-3064
4. Chintala M, Vemulapalli S, Kurowski S, Sabin C, Reynolds D, Prevete K, Friedrichs G (2008) (2008) SCH 530348, a novel oral antiplatelet agent, demonstrated no bleeding risk alone or in combination with aspirin and clopidogrel in cynomolgus monkeys. Atheroscler Thromb Vasc Biol 28:e32-e149
5. Chintala M, Strony J, Yang B, Kurowski S, Li Q (2010) SCH 602539, a protease-activated receptor-1 antagonist, inhibits thrombosis alone and in combination with cangrelor in a Folts model of arterial thrombosis in cynomolgus monkeys. Arterioscler Thromb Vasc Biol 30:2143-2149
6. Coughlin SR (1999) How the protease thrombin talks to cells. Proc Natl Acad Sci USA 96:11023-11027
7. Coughlin SR (2000) Thrombin signalling and protease-activated receptors. Nature 407:258-264
8. Davi G, Patrono C (2007) Platelet activation and atherothrombosis. N Engl J Med 357:2482-2494
9. Dubois C, Steiner B, Meyer Reigner SC (2004) Contribution of PAR-1, PAR-4 and GPIbalpha in intracellular signaling leading to the cleavage of the beta3 cytoplasmic domain during thrombin-induced platelet aggregation. Thromb Haemost 91:733-742
10. Eikelboom JW, Weitz JI, Budaj A et al (2002) Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes. Eur Heart J 23:1771-1779
11. Ghosal A, Lu X, Penner N et al (2011) Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin proteaseactivated receptor 1 antagonist. Drug Metab Dispos 39:30-38
12. Goto S, Yamaguchi T, Ikeda Y, Kato K, Yamaguchi H, Jensen P (2010a) Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH 530348 for non-ST-segment elevation acute coronary syndrome. J Atheroscler Thromb 17:156-164
13. Goto S, Ogawa H, Takeuchi M, Flather MD, Bhatt DL (2010b) Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur Heart J 31:2601-2613
14. Gurbel PA, Tantry US (2010) Combination antithrombotic therapies. Circulation 121:569-583
15. Hamilton JR, Cornelissen I, Coughlin SR (2004) Impaired hemostasis and protection against thrombosis in protease-activated receptor 4-deficient mice is due to lack of thrombin signaling in platelets. J Thromb Haemost 2:1429-1435
16. Harrington RA, Stone GW, McNulty S et al (2009) Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 361:2318-2329
17. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR (1999) Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 103:879-887
18. Kogushi M, Kobayashi H, Matsuoka T et al (2003) Antithrombotic and bleeding time effects of E5555, an orally active protease-activated receptor-1 antagonist, in guinea pigs. Circulation 108:280, Abstract
19. Kogushi M, Yokohama H, Kitamura S et al (2007) Effects of E5555, a protease-activated receptor- 1 antagonist, on the inflammatory markers in vitro. Presented at XXIst congress of the International Society on Thrombosis and Haemostasis, Geneva, Switzerland
20. Kogushi M, Matsuoka T, Kawata T et al (2011a) The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs. Eur J Pharmacol 657:131-137
21. Kogushi M, Matsuoka T, Kuramochi H et al (2011b) Oral administration of the thrombin receptor antagonist E5555 (atopaxar) attenuates intimal thickening following balloon injury in rats. Eur J Pharmacol 666:158-164
22. Leonardi S, Rao SV, Harrington RA et al (2010) Rationale and design of the randomized, doubleblind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y12-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). Am Heart J 160:65-72
23. Matsuoka T, Kogushi M, Kawata T et al (2004) Inhibitory effect of E5555, an orally active thrombin receptor antagonist, on intimal hyperplasia following balloon injury. J Am Coll Cardiol 43:68A
24. Morrow DA, Scirica BM, Fox KA et al (2009) Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2-P)-TIMI 50 trial. Am Heart J 158:335.e3-341.e3
25. Morrow DA, Braunwald E, Bonaca MP et al (2012) Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 366(15):1404-1413
26. O'Donoghue ML, Bhatt DL, Wiviott SD et al (2011) Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes/clinical perspective. Circulation 123:1843-1853
27. Patrono C, García Rodríguez LA, Landolfi R, Baigent C (2005) Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353:2373-2383
28. Serebruany VL, Kogushi M, Dastros-Pitei D, Flather M, Bhatt DL (2009) The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease. Thromb Haemost 102:111-119
29. Shinohara Y, Goto S, Doi M, Jensen P (2012) Safety of the novel protease-activated receptor-1 antagonist Vorapaxar in Japanese patients with a history of ischemic stroke. J Stroke Cerebrovasc Dis 1(4):318-24
30. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494-502
31. The TRACER Executive Steering C (2009) The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA-CER) trial: study design and rationale. Am Hear J 158:327-334
32. Tricoci P, Huang Z, Held C et al (2012) Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 366(1):20-33
33. Wallentin L, Varenhorst C, James S et al (2008) Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 29:21-30
34. Wallentin L, Becker RC, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045-1057
35. Wiviott SD, Braunwald E, McCabe CH et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001-2015
36. Wiviott SD, FlatherMD, O'DonoghueML et al (2011) Randomized trial of atopaxar in the treatment of patients with coronary artery disease/clinical perspective. Circulation 123:1854-1863